

Colorado HB 19-1131 Disclosure

Lifyorli® (relacorilant)

Corcept Therapeutics provides the following information to Colorado prescribers, as required by Colorado House Bill 19-1131.

The pricing information below reflects Corcept Therapeutics Wholesale Acquisition Costs (“WAC”) for the Corcept Therapeutics product. The WAC represents published catalogue or list price and may not represent actual transactional prices. The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Corcept Therapeutics Product

Product	NDC	Dosage Form & Strength	Package Size	WAC
Lifyorli 150 mg 9-dose supply	76346-0550-09	Capsule, one 100 mg and two 25 mg	27 capsules	\$39,226.50
Lifyorli 150 mg 1-dose supply	76346-0450-01	Capsule, one 100 mg and two 25 mg	3 capsules	\$4,358.50
Lifyorli 125 mg 9-dose supply	76346-0525-09	Capsule, one 100 mg and one 25 mg	18 capsules	\$39,226.50
Lifyorli 125 mg 1-dose supply	76346-0425-01	Capsule, one 100 mg and one 25 mg	2 capsules	\$4,358.50

The list below provides the names of prescription drugs in the same Therapeutic Class as the Corcept Therapeutics product. This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Generic Prescription Drugs in the Same Therapeutic Class*

None

* Source: Prescription Drug Data Extracted from Medi-Span. For purposes of listing the prescription drugs above, Colorado HB 19-1131 defines “Therapeutic Class” as a group of similar drugs that have the same or similar mechanism of action and are used to treat a specific condition.

Lifyorli is a registered trademark of Corcept Therapeutics Incorporated.

© 2026 Corcept Therapeutics Incorporated. All rights reserved.

US-ADM-26-0099 10-26